Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jun 25;2020(6):omaa042.
doi: 10.1093/omcr/omaa042. eCollection 2020 Jun.

Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report

Lotfollah Davoodi  1 , Hamed Jafarpour  2 , Armaghan Kazeminejad  3 , Eissa Soleymani  4 , Zahra Akbari  1 , Alireza Razavi  2
Affiliations
Case Reports

Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report

Lotfollah Davoodi et al. Oxf Med Case Reports. .

Abstract

The international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19) began in December 2019 that has affected >0.8 million individuals. Self-limiting respiratory tract involvement, severe pneumonia, multiorgan failure and death are the spectrum of COVID-19. To date, there are no especial therapeutic agents for COVID-19 infections. One such medication includes the antimalarial hydroxychloroquine (HCQ), which recently reported as a possible therapy for shortening the duration of COVID-19 symptoms, reducing inflammatory reactions to infection, impairing the exacerbation of pneumonia and boosting lung imaging findings. Like all medications, HCQ has side effects and may occur in COVID-19 patients. Here, we report on the case of a 42-year-old woman, presented with fever and dry cough, who had COVID-19 and 2 days later presented with a pruritic erythematous maculopapular rash, which started from the distal of upper extremities and rapidly, involved the entire body.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chest CT showed mild bilateral patchy GGO.
Figure 2
Figure 2
Pruritic erythematous maculopapular rash on the distal extremities due to HCQ consumption.
Figure 3
Figure 3
Small blisters on orolabial area.
Figure 4
Figure 4
Nonpruritic scalded skin.
See this image and copyright information in PMC

References

    1. World Health Organization Coronavirus disease 2019 (COVID-19): situation report, Vol. 72 World Health Organization, 2020.
    1. World Health Organization Coronavirus disease 2019 (COVID-19): situation report, Vol. 51 World Health Organization, 2020.
    1. Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020;75:491–786. - PMC - PubMed
    1. Bergin C, Philbin M, Gilvarry P, O'Connor M, King F, Adams R, et al. . Interim guidance for the use of antiviral therapy in the clinical management of acute respiratory infection with SARS-CoV-2 (COVID-19), [v2. 0]. Health Service Executive, 2020.
    1. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:1–12. - PubMed

Publication types